MAPT and Alzheimer disease: AD neurons show a heightened sensitivity to Aβ42 compared to healthy individuals, and treatment with β- or γ-secretase inhibitors has been shown to downregulate Aβ secretion and p-Tau levels [128,131,133,135,139,140].